Anixa Biosciences Beheer
Beheer criteriumcontroles 2/4
De CEO Anixa Biosciences is Amit Kumar, benoemd in Jul2017, heeft een ambtstermijn van 7.33 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 3.64M, bestaande uit 19.8% salaris en 80.2% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 1.61% van de aandelen van het bedrijf, ter waarde $ 1.65M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 7.7 jaar en 6.1 jaar.
Belangrijke informatie
Amit Kumar
Algemeen directeur
US$3.6m
Totale compensatie
| Percentage CEO-salaris | 19.8% |
| Dienstverband CEO | 7.3yrs |
| Eigendom CEO | 1.6% |
| Management gemiddelde ambtstermijn | 7.7yrs |
| Gemiddelde ambtstermijn bestuur | 6.1yrs |
Recente managementupdates
Recent updates
We're Not Very Worried About Anixa Biosciences' (NASDAQ:ANIX) Cash Burn Rate
Sep 12
We're Hopeful That Anixa Biosciences (NASDAQ:ANIX) Will Use Its Cash Wisely
May 23We're Not Worried About Anixa Biosciences' (NASDAQ:ANIX) Cash Burn
Jan 19We Think Anixa Biosciences (NASDAQ:ANIX) Can Easily Afford To Drive Business Growth
Oct 06Is There An Opportunity With Anixa Biosciences, Inc.'s (NASDAQ:ANIX) 41% Undervaluation?
Apr 27Are Investors Undervaluing Anixa Biosciences, Inc. (NASDAQ:ANIX) By 36%?
Jan 13We're Interested To See How Anixa Biosciences (NASDAQ:ANIX) Uses Its Cash Hoard To Grow
Sep 26Anixa adds 11% after dosing initiation in CAR-T ovarian cancer trial
Aug 15Anixa to get additional US patent linked to breast cancer vaccine technology
Jul 21Anixa Biosciences (NASDAQ:ANIX) Is In A Good Position To Deliver On Growth Plans
Jun 13Anixa: Making Sense Of A Bullish Move Up In Bearish Biotech Times
May 11We're Interested To See How Anixa Biosciences (NASDAQ:ANIX) Uses Its Cash Hoard To Grow
Feb 24Companies Like Anixa Biosciences (NASDAQ:ANIX) Can Afford To Invest In Growth
Oct 28Our First Look At Anixa Biosciences
Sep 23Here's Why We're Not At All Concerned With Anixa Biosciences' (NASDAQ:ANIX) Cash Burn Situation
Jun 12OntoChem assigns Anixa covid-19 drug discovery project to MolGenie
May 07Anixa Biosciences (NASDAQ:ANIX) Is In A Good Position To Deliver On Growth Plans
Jan 13
Anixa Biosciences, Cleveland Clinic in ovarian cancer vaccine pact
Dec 01Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Jul 31 2024 | n/a | n/a | -US$12m |
| Apr 30 2024 | n/a | n/a | -US$12m |
| Jan 31 2024 | n/a | n/a | -US$11m |
| Oct 31 2023 | US$4m | US$720k | -US$10m |
| Jul 31 2023 | n/a | n/a | -US$11m |
| Apr 30 2023 | n/a | n/a | -US$11m |
| Jan 31 2023 | n/a | n/a | -US$12m |
| Oct 31 2022 | US$2m | US$631k | -US$14m |
| Jul 31 2022 | n/a | n/a | -US$14m |
| Apr 30 2022 | n/a | n/a | -US$16m |
| Jan 31 2022 | n/a | n/a | -US$15m |
| Oct 31 2021 | US$11m | US$573k | -US$13m |
| Jul 31 2021 | n/a | n/a | -US$11m |
| Apr 30 2021 | n/a | n/a | -US$9m |
| Jan 31 2021 | n/a | n/a | -US$10m |
| Oct 31 2020 | US$2m | US$522k | -US$10m |
| Jul 31 2020 | n/a | n/a | -US$10m |
| Apr 30 2020 | n/a | n/a | -US$9m |
| Jan 31 2020 | n/a | n/a | -US$9m |
| Oct 31 2019 | US$665k | US$476k | -US$12m |
| Jul 31 2019 | n/a | n/a | -US$15m |
| Apr 30 2019 | n/a | n/a | -US$18m |
| Jan 31 2019 | n/a | n/a | -US$17m |
| Oct 31 2018 | US$12m | US$425k | -US$14m |
Compensatie versus markt: De totale vergoeding ($USD 3.64M ) Amit } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 649.63K ).
Compensatie versus inkomsten: De vergoeding van Amit is gestegen terwijl het bedrijf verliesgevend is.
CEO
Amit Kumar (60 yo)
7.3yrs
Tenure
US$3,639,651
Compensatie
Dr. Amit Kumar, Ph.D. was a Director at Ascent Solar Technologies, Inc. since June 2007 until September 16, 2022 and had been its Independent Chairman of the Board since January 2011 until September 16, 20...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| CEO, Chairman & Co-Chair of CBAB | 7.3yrs | US$3.64m | 1.61% $ 1.7m | |
| President | 8yrs | US$1.97m | 0.11% $ 112.7k | |
| Senior Vice President of Engineering | 12.2yrs | US$275.00k | geen gegevens | |
| Chief Development Officer & Chair Breast Cancer Clinical Advisory Board | 3.2yrs | geen gegevens | geen gegevens |
7.7yrs
Gemiddelde duur
64.5yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van ANIX is doorgewinterd en ervaren (gemiddelde ambtstermijn van 7.7 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| CEO, Chairman & Co-Chair of CBAB | 12yrs | US$3.64m | 1.61% $ 1.7m | |
| Chief Development Officer & Chair Breast Cancer Clinical Advisory Board | 1.8yrs | geen gegevens | geen gegevens | |
| Lead Independent Director | 7.3yrs | US$169.35k | 2.84% $ 2.9m | |
| Member of Scientific Advisory Board | no data | geen gegevens | geen gegevens | |
| Member of Scientific Advisory Board | 6.1yrs | geen gegevens | geen gegevens | |
| Member of Scientific Advisory Board | 5.1yrs | geen gegevens | geen gegevens | |
| Member of Breast Cancer Clinical Advisory Board | 1.8yrs | geen gegevens | geen gegevens | |
| Member of SAB & Breast Cancer Clinical Advisory Board | 6.2yrs | US$169.35k | 0.36% $ 368.0k | |
| Member of Scientific Advisory Board | 6.1yrs | geen gegevens | geen gegevens | |
| Member of Scientific Advisory Board | 6.1yrs | geen gegevens | geen gegevens | |
| Member of Scientific Advisory Board | 6.1yrs | geen gegevens | geen gegevens | |
| Independent Director | 5.1yrs | US$169.35k | 0.14% $ 146.1k |
6.1yrs
Gemiddelde duur
70yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van ANIX wordt beschouwd als ervaren (gemiddelde ambtstermijn 6.1 jaar).